Health Economics›Pancreatic cancer›Metastatic disease first-line

Metastatic disease first-line

Pancreatic cancer · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Gemcitabine and nab-Paclitaxel Variant #02	—	R 184 204	56d	—	11.6 mo	—	—	8
Erlotinib and Gemcitabine Variant #03	—	R 55 934	56d	—	6.1 mo	—	—	2
Capecitabine and Gemcitabine Variant #06	—	R 17 897	56d	—	7.9 mo	—	—	4
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	7.4 mo	—	—	1
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	5.7 mo	6.6 mo	4	R 56 851 PFS proxy	21
Gemcitabine and Nimotuzumab Variant #01 Partial	—	R 8 528	56d	—	10.9 mo	—	—	—
GTX Variant #01	—	R 4 527	21d	—	—	—	—	—
FOLFIRINOX Variant #03	—	R 3 740	14d	—	11.4 mo	—	—	2
PEFG Variant #01	—	R 3 546	28d	—	—	—	—	1
GemOx Variant #01	—	R 2 335	14d	5.8 mo	9.0 mo	13	R 30 358 PFS proxy	2
NALIRIFOX Variant #01 Partial	—	R 2 262	14d	—	11.1 mo	—	—	1
Capecitabine monotherapy Variant #17	—	R 2 219	21d	—	—	—	—	2
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	4.4 mo	—	—	—
S-1 monotherapy Variant #01 Partial	—	—	21d	—	9.7 mo	—	—	1

14 of 14 regimens shown